drugset / Trial / NCT06233201

Sitagliptin and Metformin Hydrochloride Tablets 50 mg/500 mg Relative to Originator

NCT06233201

Phase 1 Unknown 34 enrolled Bio-innova Co., Ltd
RandomizedCrossoverOpen-labelBasic science

Summary

The study is to compare the rate and extent of absorption of a generic formulation with that of a reference for mulation when given as equal labeled dose. The study will be randomized, open-label, single dose, two way crossover design with two-period, two-treatment and two-sequence under fed condition and at least 7 days washout period between the doses.

Timeline

Start
2024-06-04
Primary completion
2024-07-14
Completion
2024-07-28

Drugs

EvaluationDrugModalityDoseRoute
Subject Metformin Small molecule 500 mg Oral
Subject Sitagliptin Small molecule 50 mg Oral

Indications

No indication recorded.